Conservative Balance SheetEssentially no debt and a large equity base provide durable financial flexibility. Over a 2–6 month horizon this reduces refinancing risk, allows the company to absorb valuation swings in portfolio holdings, and preserves capacity to fund follow-on investments or support portfolio companies without external borrowing.

Life-science Focused Investment ModelA focused investment mandate in medtech, biotech and pharma creates sector expertise and deal flow advantages. Active support of portfolio companies can improve exit outcomes and value creation, making returns more sustainable than passive holdings over the medium term.

Revenue Rebound And Solid Gross MarginA sharp revenue rebound and high gross margin indicate underlying portfolio assets can generate operating value and scalable economics. Sustained margin strength supports the ability to retain earnings and reinvest in holdings, aiding long-term value realization and resilience through cycles.

Bears Say

Large Net Loss And Earnings VolatilityA very large 2025 net loss and multi-year earnings swings demonstrate weak earnings quality and predictability. This undermines confidence in recurring returns from the investment portfolio, risks erosion of equity over time, and complicates planning for exits or distributions.

Uneven Cash Generation; FCF Fell To ZeroZero free cash flow in 2025 signals limited internal liquidity to fund operations, support portfolio companies, or pursue new investments without realizing assets. Persistent cash volatility increases reliance on timing of exits and can force value-destroying sales under pressure.

Inconsistent Shareholder ReturnsLarge swings in shareholder returns highlight cyclical performance tied to exit timing and fair-value movements. This inconsistency reduces reliability of distributions and makes forecasting NAV-based returns difficult for investors over a medium-term horizon.

6ZB FAQ

What was Linc AB’s price range in the past 12 months?

Linc AB lowest stock price was €5.43 and its highest was €7.37 in the past 12 months.

What is Linc AB’s market cap?

Linc AB’s market cap is €359.28M.

When is Linc AB’s upcoming earnings report date?

Linc AB’s upcoming earnings report date is Apr 28, 2026 which is in 52 days.

How were Linc AB’s earnings last quarter?

Linc AB released its earnings results on Jan 22, 2026. The company reported -€0.177 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.177.

Is Linc AB overvalued?

According to Wall Street analysts Linc AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Linc AB pay dividends?

Linc AB does not currently pay dividends.

What is Linc AB’s EPS estimate?

Linc AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Linc AB have?

Linc AB has 57,910,446 shares outstanding.

What happened to Linc AB’s price movement after its last earnings report?

Linc AB reported an EPS of -€0.177 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.675%.

Which hedge fund is a major shareholder of Linc AB?

Currently, no hedge funds are holding shares in DE:6ZB

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Linc AB

Linc AB is a private equity and venture capital firm, specializing in early, mid and late venture investments in pharmaceutical, life-science and med-tech companies, respectively. The firm prefers to invest in Nordic companies. It usually invests from SEK 25 million to SEK 250 million, the first investment often being a relatively small one and the follow-up investments comprising the larger part of the investment. Linc AB is based in Stockholm, Sweden.private eequity and venture capital firm, specializing in early, mid and late venture investments in pharmaceutical, life-science and med-tech companies, respectively. The firm prefers to invest in Nordic companies. It usually invests from SEK 25 million to SEK 250 million, the first investment often being a relatively small one and the follow-up investments comprising the larger part of the investment. Linc AB is based in Stockholm, Sweden.